Tech

    BOM, imec.istart, Graduate Ventures and RoundOne put €500k into TU/e robotics spinout Syntric Medical

    Syntric Medical, a spinout from Eindhoven University of Technology, has raised €500,000 in pre-seed funding from four investors for a robotic system that guides needle placement using live CT images. The round stays open to further investors until 31 December 2026.

    T

    The Cap Table

    17 November 20263 min read
    BOM, imec.istart, Graduate Ventures and RoundOne put €500k into TU/e robotics spinout Syntric Medical

    Syntric Medical, a spinout from Eindhoven University of Technology, has raised €500,000 in pre-seed funding from four investors for a robotic system that guides needle placement using live CT images. The round stays open to further investors until 31 December 2026.

    Syntric Medical builds a patented robotic platform that helps an interventional radiologist place a needle correctly on the first attempt, even in very small targets. The system works with live CT images and accounts for the way an abnormality shifts as the patient breathes, according to a press release from BOM, the Brabant development agency and one of the backers.

    The company is starting with lung biopsies, where small spots can be hard to sample because of respiratory movement. An inconclusive biopsy can mean a repeat procedure and a delay in diagnosis, BOM said. Syntric Medical plans to apply the same technology to other procedures in the chest and abdomen where breathing makes needle placement difficult, with liver ablation given as an example.

    The deal

    The €500,000 pre-seed round comes from BOM, imec.istart, Graduate Ventures and RoundOne. BOM said each investor brings its own expertise to the company, and that the round remains open to investors until 31 December 2026.

    The money is earmarked for further development and preclinical validation of the platform. Syntric Medical will also seek early feedback from the US Food and Drug Administration through a pre-submission process, and test how much demand there is among healthcare providers and what they would be willing to pay. BOM noted that these steps are meant to validate the technology and its route to adoption, and do not amount to regulatory approval.

    "With this investment we can move our technology a step closer to the patient," said chief executive Joric Oude Vrielink.

    The investors' view

    Auke van den Hout, managing partner at Graduate Ventures, pointed to the team's robotics background at TU/e combined with a clear view of what radiologists need. Paul Vernooij, investment manager at BOM, framed the deal as part of the agency's strategy of investing early to help medical technology reach patients and to build the region's medtech ecosystem.

    What comes next

    The next steps set out in the release are preclinical validation, the FDA pre-submission and a check on provider demand and willingness to pay. The company's stated mission is to make accurate needle placement simple across interventional radiology, with lung cancer diagnosis as the starting point.


    Original source: BOM, "Syntric Medical aims to make lung cancer diagnosis more reliable" (press release)

    T

    Written by

    The Cap Table

    Stay in the loop

    Get the biggest stories from the Dutch startup ecosystem straight to your inbox. No spam, just what matters.

    Related stories

    Rise Europe landscape lists 20 Dutch firms among 168 ventures as 70% of late-stage deep tech cash comes from outside Europe
    Tech

    Rise Europe landscape lists 20 Dutch firms among 168 ventures as 70% of late-stage deep tech cash comes from outside Europe

    Twenty Dutch companies feature among the 168 ventures profiled in Rise Europe's European Startup & Scaleup Landscape 2026, with quantum technology, photonics and advanced manufacturing the strongest Dutch clusters. The report, citing research by Lakestar, Walden Catalyst Ventures and Dealroom, says roughly 70% of late-stage funding for European deep tech still comes from outside Europe.

    The Cap Table·18 October 2026